US 12,419,904 B2
Medical use of tafoxiparin
Lena Degling-Wikingsson, Spånga (SE); and Gunvor Ekman-Ordeberg, Danderyd (SE)
Assigned to DILAFOR AB, Solna (SE)
Filed by DILAFOR AB, Solna (SE)
Filed on Feb. 4, 2025, as Appl. No. 19/045,102.
Application 19/045,102 is a continuation of application No. 18/142,121, filed on May 2, 2023.
Claims priority of application No. 22171313 (EP), filed on May 3, 2022; and application No. 23164674 (EP), filed on Mar. 28, 2023.
Prior Publication US 2025/0177435 A1, Jun. 5, 2025
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/737 (2006.01); A61P 15/04 (2006.01)
CPC A61K 31/737 (2013.01) [A61P 15/04 (2018.01)] 30 Claims
 
1. A method for the spontaneous onset of labor in a term pregnant woman in need thereof, the method comprising administering a therapeutically effective amount of tafoxiparin in a daily dose of 150 to 320 mg per day, as a monotherapy, to said term pregnant woman.